Protein Summary
Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex required for mitotic progression and cytokinesis. The BCR(KLHL9-KLHL13) E3 ubiquitin ligase complex mediates the ubiquitination of AURKB and controls the dynamic behavior of AURKB on mitotic chromosomes and thereby coordinates faithful mitotic progression and completion of cytokinesis. This gene encodes a BTB and kelch domain containing protein and belongs to the kelch repeat domain containing superfamily of proteins. The encoded protein functions as an adaptor protein that complexes with Cullin 3 and other proteins to form the Cullin 3-based E3 ubiquitin-protein ligase complex. This complex is necessary for proper chromosome segregation and completion of cytokinesis. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Mar 2010]
- ENST00000262820
- ENSP00000262820
- ENSG00000003096
- ENST00000469946
- ENSP00000419803
- ENST00000540167
- ENSP00000441029
- ENST00000541812
- ENSP00000444450
- ENST00000545703
- ENSP00000440707
- BKLHD2
- KIAA1309
- BKLHD2
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
protein domain | 0.92 | ||
transcription factor perturbation | 0.8 | ||
virus perturbation | 0.79 | ||
trait | 0.75 | ||
cell type or tissue | 0.63 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 4.32 (req: < 5)
Gene RIFs: 0 (req: <= 3)
Antibodies: 126 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 4.32 (req: >= 5)
Gene RIFs: 0 (req: > 3)
Antibodies: 126 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 5
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0